Journal
CANCER JOURNAL
Volume 16, Issue 4, Pages 295-303Publisher
LIPPINCOTT WILLIAMS & WILKINS
DOI: 10.1097/PPO.0b013e3181eb5066
Keywords
immunotherapy; chemotherapy; chemoimmunotherapy; cancer vaccines; adoptive cellular therapy; clinical trials
Categories
Funding
- Department of Defense [W81XWH-04-1-0595, W81XWH-07-1-0485]
- Breast SPORE program [P50 CA88843]
- National Institutes of Health [K23 CA098498-01]
- American Cancer Society [RSG CCE-112685]
- Komen for the Cure [BCTR0707297]
- AVON Foundation
- Gateway Foundation for Cancer Research
- V Foundation for Cancer Research
- Climb for Hope
Ask authors/readers for more resources
Cancer chemotherapy drugs are historically regarded as detrimental to immunity because of their myelosuppressive effects. However, accumulating data suggest that the antitumor activity of conventional cancer chemotherapy results in part from its ability to harness the innate and adaptive immune systems by inducing immunologically active tumor cell death. Additional data broaden the immunologic effect of cancer chemotherapy drugs, demonstrating that some drugs have the ability to disrupt pathways of immune suppression and immune tolerance in a manner that depends on the drug dose, and the timing of its administration in relation to immunotherapy. Understanding the cellular and molecular basis of the interactions between chemotherapy drugs and the immune system will facilitate the strategic development of chemoimmunotherapy treatment regimens that both maximize tumor regression and the antitumor immune response for the long-term clinical benefit of cancer patients.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available